Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.

Azidus Brasil347 enrolled

Overview

This a open, prospective, multicenter, single-arm, phase III study for clinical assessment of anti-Rh immunoglobulin (KamRho-D®) in Rh and Coombs negative women with risk sensitization. The anti-Rh immunoglobulin is an immunobiological containing high concentration of specific antibodies against factor D and "neutralizes" D antigen present in the Rh-positive fetal red blood cells (Rh +), which passed into the bloodstream of Rh-negative pregnant women (Rh).

This a phase III study in which women participants with RH and Coombs negative will receive only one dose of 1500 IU anti-Rh immunoglobulin intramuscularly up to 72 hours post exposition (child-birth) and will be following until six months to verification of negative Coombs maintenance. Safety evaluation data will include report of all adverse events (including type, frequency, intensity, seriousness, severity and action taken related to the investigational product).

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

347

Conditions

Pregnancy; Fetomaternal Hemorrhage

Interventions

Immunoglobulin Anti-RhDBIOLOGICAL

Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).

Eligibility

Sex: FEMALEMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Agree to participate, sign and date ICF; * 18 years old or older; * Mothers who are Rh-negative, negative indirect Coombs analyzed by gel agglutination method, whose just deliveries Rh positive baby. Exclusion Criteria: * Be participating simultaneously or have participated in another clinical trial within the last 12 months; * Mothers who are allergic to any components of the formula; * Mothers who have a history of IgA deficiency or IgA antibody present; * Mothers who have a history of autoimmune hemolytic anemia with hemolysis or with pre-existing risk of hemolysis; * Mothers who have indirect Coombs test positive at the beginning of the treatment; * Rh-negative mothers whose delivered Rh-negative babies; * Abnormalities of the coagulation system; * Patients who made use of vaccines made with live pathogens in the last 03 months or will make during the study; * Patients with clinical diagnosis of prenatal liver and / or severe nephropathy; * Principal Investigator of the study criteria.

Locations (5)

Centro de Pesquisa da MEAC - Maternidade Escola Assis Chateaubriand

Fortaleza, Ceará, Brazil

Instituto Tropical de Medicina Reprodutiva e Menopausa -INTRO

Cuiabá, Mato Grosso, Brazil

Associação Educadora São Carlos AESC - Centro de Pesquisa HRPC

Canoas, Rio Grande do Sul, Brazil

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Outcomes

Primary Outcomes

Negative result for coombs test up to six months after immunization

Will be evaluated by proportion of participants that presented negative result for coombs test until six months after passive immunization with investigational product.

Time frame: up to six months

Secondary Outcomes

Adverse Events Report

Safety of human immunoglobulin anti-RhD will be verified through adverse events reported by participants throughout study. The adverse events will be classified about the type, frequency, intensity, seriousness, severity and relation to the study drug.

Time frame: up to six months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.